WARREN, N.J., Aug. 30, 2011 (GLOBE NEWSWIRE) -- MonoSol Rx, LLC (“MonoSol Rx”), the developer of PharmFilm® drug delivery technology, today announced that the Company plans to develop a second oral film product for the treatment of attention-deficit hyperactivity disorder (ADHD) with its partner KemPharm, Inc. (“KemPharm”), a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of ADHD, pain, and other central nervous system disorders. KP415, which was recently discovered by KemPharm, is a novel prodrug of methylphenidate, a commonly used medication for the treatment of ADHD.
